Published in J Acquir Immune Defic Syndr on March 01, 2012
Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy. Arch Dis Child (2012) 1.73
Metabolic complications and treatment of perinatally HIV-infected children and adolescents. J Int AIDS Soc (2013) 1.09
High prevalence of lipoatrophy in pre-pubertal South African children on antiretroviral therapy: a cross-sectional study. BMC Pediatr (2012) 1.08
Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy. Pediatr Infect Dis J (2015) 0.83
The physical and psychological effects of HIV infection and its treatment on perinatally HIV-infected children. J Int AIDS Soc (2015) 0.79
High Prevalence of Dyslipidemia and Insulin Resistance in HIV-infected Prepubertal African Children on Antiretroviral Therapy. Pediatr Infect Dis J (2016) 0.78
Long-term body composition and metabolic changes in HIV-infected children switched from stavudine to tenofovir and from protease inhibitors to efavirenz. Eur J Pediatr (2013) 0.78
Biceps skin-fold thickness may detect and predict early lipoatrophy in HIV-infected children. Pediatr Infect Dis J (2013) 0.77
Long-Term Changes of Subcutaneous Fat Mass in HIV-Infected Children on Antiretroviral Therapy: A Retrospective Analysis of Longitudinal Data from Two Pediatric HIV-Cohorts. PLoS One (2015) 0.75
Getting to 90-90-90 in paediatric HIV: What is needed? J Int AIDS Soc (2015) 0.75
Effect of reducing the paediatric stavudine dose by half: a physiologically-based pharmacokinetic model. Int J Antimicrob Agents (2015) 0.75
Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med (2003) 12.23
The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med (2003) 10.84
Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet (1999) 7.08
Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med (2001) 6.01
Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years--United States, 2008. MMWR Recomm Rep (2008) 4.64
Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet (1998) 3.22
Guidelines for the use of antiretroviral agents in pediatric HIV infection, January 7, 2000. HIV Clin Trials (2001) 3.15
Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS (2001) 2.73
Mortality in HIV-infected and uninfected children of HIV-infected and uninfected mothers in rural Uganda. J Acquir Immune Defic Syndr (2006) 2.66
An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet (2003) 2.43
A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS (2006) 2.35
Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. BMJ (2003) 2.34
Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS (2000) 2.31
Distribution of lipoproteins by age and gender in adolescents. Circulation (2006) 2.24
Fat distribution in women with HIV infection. J Acquir Immune Defic Syndr (2006) 2.15
Morbidity and mortality in European children vertically infected by HIV-1. The French Pediatric HIV Infection Study Group and European Collaborative Study. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 1.74
Metabolic function and the prevalence of lipodystrophy in a population of HIV-infected African subjects receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 1.70
Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS (2003) 1.69
Fat distribution and metabolic changes in patients with HIV infection. AIDS (1999) 1.67
Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr (2003) 1.65
Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in Western India. J Acquir Immune Defic Syndr (2005) 1.64
Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS (2001) 1.63
Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS (2004) 1.61
Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis (2002) 1.57
Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet (2001) 1.55
HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J Biol Chem (2001) 1.53
Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. AIDS (2004) 1.47
Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS (2001) 1.45
Metabolic abnormalities and use of HIV-1 protease inhibitors. Lancet (1998) 1.44
Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine. J Acquir Immune Defic Syndr (2005) 1.42
Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIV-infected children. J Acquir Immune Defic Syndr (2005) 1.41
Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study. Antivir Ther (2005) 1.36
Indinavir induces acute and reversible peripheral insulin resistance in rats. Diabetes (2002) 1.28
Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr (2002) 1.27
Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS (2002) 1.25
Prevalence of lipodystrophy in HIV-infected children: a cross-sectional study. Eur J Pediatr (2006) 1.18
Antiretroviral pharmacokinetic profile: a review of sex differences. Gend Med (2007) 1.17
Lipodystrophy syndrome in human immunodeficiency virus-infected children. Pediatr Infect Dis J (2002) 1.16
Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients. Antivir Ther (2003) 1.14
Serum lipids, glucose homeostasis and abdominal adipose tissue distribution in protease inhibitor-treated and naive HIV-infected children. AIDS (2003) 1.12
A longitudinal study of the changes in body fat and metabolic parameters in a South African population of HIV-positive patients receiving an antiretroviral therapeutic regimen containing stavudine. AIDS Res Hum Retroviruses (2009) 1.10
Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children. AIDS (2000) 1.09
Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe d'Epidémiologie Clinique du Syndrome d'Immunodéficience Acquise en Aquitaine. Clin Infect Dis (2000) 1.09
Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children. Eur J Pediatr (2005) 1.07
Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy. AIDS (1999) 1.05
The relationship between lipodystrophy-associated body changes and measures of quality of life and mental health for HIV-positive adults. Qual Life Res (2005) 1.04
Self-perception of body fat changes and HAART adherence in the Women's Interagency HIV Study. AIDS Behav (2008) 1.04
Lipodystrophy in HIV-infected children is associated with high viral load and low CD4+ -lymphocyte count and CD4+ -lymphocyte percentage at baseline and use of protease inhibitors and stavudine. J Acquir Immune Defic Syndr (2001) 1.00
Stavudine versus zidovudine and the development of lipodystrophy. J Acquir Immune Defic Syndr (2001) 1.00
Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients. Clin Infect Dis (2002) 0.97
Epidemiology, clinical features, and prognostic factors of paediatric HIV infection. Italian Multicentre Study. Lancet (1988) 0.95
Evidence of human immunodeficiency virus-associated lipodystrophy syndrome in children treated with protease inhibitors. Pediatr Infect Dis J (2003) 0.90
Evaluation of the risk factors associated with lipodystrophy development in a cohort of HIV-positive patients. Antivir Ther (2002) 0.90
The effect of individual antiretroviral drugs on body composition in HIV-infected persons initiating highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2009) 0.86
Lipodystrophy and metabolic complications of highly active antiretroviral therapy. Indian J Pediatr (2009) 0.85
Adipokine profiles and lipodystrophy in HIV-infected children during the first 4 years on highly active antiretroviral therapy. HIV Med (2011) 0.81
The HIV protease inhibitor ritonavir increases lipoprotein production and has no effect on lipoprotein clearance in mice. J Lipid Res (2002) 0.80
Facial lipoatrophy: appearances are not deceiving. J Assoc Nurses AIDS Care (2009) 0.78
Correction of facial lipoatrophy using autologous fat transplants in HIV-infected adolescents. HIV Med (2009) 0.78
Epidemiology of HIV infection in children in Italy. The Italian Register for HIV Infection in Children. Acta Paediatr Suppl (1994) 0.77
Rapid development of central adiposity after postexposure prophylaxis with antiretroviral drugs: a proof of principle? AIDS (2003) 0.77
Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS (2008) 4.48
Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS (2007) 2.80
Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000-2011. AIDS (2014) 2.67
Response to combination antiretroviral therapy: variation by age. AIDS (2008) 2.28
Effect of month of birth on the risk of suicide. Br J Psychiatry (2006) 2.19
Risk of triple-class virological failure in children with HIV: a retrospective cohort study. Lancet (2011) 1.90
Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women. Clin Infect Dis (2007) 1.88
Disease progression in children with vertically-acquired HIV infection in sub-Saharan Africa: reviewing the need for HIV treatment. Curr HIV Res (2007) 1.85
How active are our children? Findings from the Millennium Cohort Study. BMJ Open (2013) 1.49
High incidence of invasive group B streptococcal infections in HIV-exposed uninfected infants. Pediatrics (2010) 1.47
CD4 cell response to antiretroviral therapy in children with vertically acquired HIV infection: is it associated with age at initiation? J Infect Dis (2006) 1.46
Is there a difference in the efficacy of peripartum antiretroviral regimens in reducing mother-to-child transmission of HIV in Africa? AIDS (2005) 1.41
Association between prenatal treatment and clinical manifestations of congenital toxoplasmosis in infancy: a cohort study in 13 European centres. Acta Paediatr (2005) 1.39
Antiretroviral therapy and congenital abnormalities in infants born to HIV-infected women in the UK and Ireland, 1990-2007. AIDS (2009) 1.36
Uninfected but not unaffected: chronic maternal infections during pregnancy, fetal immunity, and susceptibility to postnatal infections. Lancet Infect Dis (2012) 1.33
Estimating the efficacy of interventions to prevent mother-to-child transmission of human immunodeficiency virus in breastfeeding populations: comparing statistical methods. Am J Epidemiol (2003) 1.33
Does highly active antiretroviral therapy increase the risk of congenital abnormalities in HIV-infected women? J Acquir Immune Defic Syndr (2005) 1.32
Genetic and epigenetic factors at COL2A1 and ABCA4 influence clinical outcome in congenital toxoplasmosis. PLoS One (2008) 1.32
Large meta-analysis establishes the ACE insertion-deletion polymorphism as a marker of Alzheimer's disease. Am J Epidemiol (2005) 1.28
Age-related standards for total lymphocyte, CD4+ and CD8+ T cell counts in children born in Europe. Pediatr Infect Dis J (2005) 1.23
Quality control methods in accelerometer data processing: defining minimum wear time. PLoS One (2013) 1.23
Actigraph accelerometer-defined boundaries for sedentary behaviour and physical activity intensities in 7 year old children. PLoS One (2011) 1.22
The double burden of obesity and malnutrition in a protracted emergency setting: a cross-sectional study of Western Sahara refugees. PLoS Med (2012) 1.20
Epistasis in sporadic Alzheimer's disease. Neurobiol Aging (2008) 1.19
Prevalence of lipodystrophy in HIV-infected children: a cross-sectional study. Eur J Pediatr (2006) 1.18
Antiretroviral therapy-associated modulation of Th1 and Th2 immune responses in HIV-infected pregnant women. J Reprod Immunol (2006) 1.16
Treating HIV-infected mothers reduces under 5 years of age mortality rates to levels seen in children of HIV-uninfected mothers in rural South Africa. Antivir Ther (2012) 1.13
Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. Arch Intern Med (2010) 1.12
Reproductive experience of HIV-infected women living in Europe. Hum Reprod (2008) 1.12
Maternal HIV infection associated with small-for-gestational age infants but not preterm births: evidence from rural South Africa. Hum Reprod (2012) 1.12
Higher rates of post-partum complications in HIV-infected than in uninfected women irrespective of mode of delivery. AIDS (2004) 1.10
Nonlinear growth generates age changes in the moments of the frequency distribution: the example of height in puberty. Biostatistics (2007) 1.09
Maternal and infant factors and lymphocyte, CD4 and CD8 cell counts in uninfected children of HIV-1-infected mothers. AIDS (2005) 1.08
Prevention of mother-to-child transmission of HIV infection: Ukraine experience to date. Eur J Public Health (2006) 1.08
25-Hydroxyvitamin D and pre-clinical alterations in inflammatory and hemostatic markers: a cross sectional analysis in the 1958 British Birth Cohort. PLoS One (2010) 1.06
Increasing likelihood of further live births in HIV-infected women in recent years. BJOG (2005) 1.05
Pregnancy and HIV infection: A european consensus on management. AIDS (2002) 1.04
Predominant influence of environmental determinants on the persistence and avidity maturation of antibody responses to vaccines in infants. J Infect Dis (2006) 1.04
Within and between race differences in lymphocyte, CD4+, CD8+ and neutrophil levels in HIV-uninfected children with or without HIV exposure in Europe and Uganda. Ann Trop Paediatr (2006) 1.03
Tuberculosis and HIV co-infection in children. BMC Infect Dis (2014) 1.00
Prevalence of sexually transmitted infections in HIV-1 infected pregnant women in Europe. Eur J Epidemiol (2007) 0.99
Effectiveness of early initiation of protease inhibitor-sparing antiretroviral regimen in human immunodeficiency virus-1 vertically infected infants. Pediatr Infect Dis J (2007) 0.98
Fertility intentions of HIV-infected women in the United Kingdom. AIDS Care (2011) 0.97
Age- and sex-related reference ranges of alanine aminotransferase levels in children: European paediatric HCV network. J Pediatr Gastroenterol Nutr (2009) 0.97
Incidence, patterns, and predictors of repeat pregnancies among HIV-infected women in the United Kingdom and Ireland, 1990-2009. J Acquir Immune Defic Syndr (2012) 0.96
Does exposure to antiretroviral therapy affect growth in the first 18 months of life in uninfected children born to HIV-infected women? J Acquir Immune Defic Syndr (2005) 0.96
Cholecalciferol supplementation in HIV-infected youth with vitamin D insufficiency: effects on vitamin D status and T-cell phenotype: a randomized controlled trial. HIV Clin Trials (2013) 0.95
Seroreversion in children infected with HIV type 1 who are treated in the first months of life is not a rare event. Clin Infect Dis (2005) 0.95
National Guidelines for the prevention of mother-to-child transmission of HIV across Europe - how do countries differ? Eur J Public Health (2013) 0.95
Use of zidovudine-sparing HAART in pregnant HIV-infected women in Europe: 2000-2009. J Acquir Immune Defic Syndr (2011) 0.94
Maternal cognitions and mother-infant interaction in postnatal depression and generalized anxiety disorder. J Abnorm Psychol (2012) 0.93
Transferrin and HFE genes interact in Alzheimer's disease risk: the Epistasis Project. Neurobiol Aging (2010) 0.93
Predictors of pregnancy and changes in pregnancy incidence among HIV-positive women accessing HIV clinical care. AIDS (2013) 0.92
Relative acidic compartment volume as a lysosomal storage disorder-associated biomarker. J Clin Invest (2014) 0.92
Eating habits and attitudes among 10-year-old children of mothers with eating disorders: longitudinal study. Br J Psychiatry (2006) 0.92
Insufficient antiretroviral therapy in pregnancy: missed opportunities for prevention of mother-to-child transmission of HIV in Europe. Antivir Ther (2011) 0.92
Identification of patients with high-risk lymph node-negative colorectal cancer and potential benefit from adjuvant chemotherapy. Jpn J Clin Oncol (2004) 0.92
Seasonal variation in respiratory syncytial virus epidemics in the Gambia, West Africa. Pediatr Infect Dis J (2004) 0.92
Predictors of non-response in a UK-wide cohort study of children's accelerometer-determined physical activity using postal methods. BMJ Open (2013) 0.91
Cell-free (RNA) and cell-associated (DNA) HIV-1 and postnatal transmission through breastfeeding. PLoS One (2012) 0.91
The association between ethnicity and late presentation to antenatal care among pregnant women living with HIV in the UK and Ireland. AIDS Care (2012) 0.91
When t-tests or Wilcoxon-Mann-Whitney tests won't do. Adv Physiol Educ (2010) 0.91
Rubella susceptibility among pregnant women in North London, 1996-1999. J Public Health Med (2002) 0.91
Intussusception incidence among infants in the UK and Republic of Ireland: a pre-rotavirus vaccine prospective surveillance study. Vaccine (2013) 0.90
Use of combination neonatal prophylaxis for the prevention of mother-to-child transmission of HIV infection in European high-risk infants. AIDS (2013) 0.90
Pregnancies in young women with vertically acquired HIV infection in Europe. AIDS (2007) 0.89
Predictors of retinochoroiditis in children with congenital toxoplasmosis: European, prospective cohort study. Pediatrics (2008) 0.89
Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med (2003) 0.89
Impact of expanded access to combination antiretroviral therapy in pregnancy: results from a cohort study in Ukraine. Bull World Health Organ (2013) 0.89
Antiretroviral therapy in pregnancy: balancing the risk of preterm delivery with prevention of mother-to-child HIV transmission. Antivir Ther (2010) 0.89
Replication by the Epistasis Project of the interaction between the genes for IL-6 and IL-10 in the risk of Alzheimer's disease. J Neuroinflammation (2009) 0.89
Characteristics and management of HIV-1-infected pregnant women enrolled in a randomised trial: differences between Europe and the USA. BMC Infect Dis (2007) 0.89
Treatment and disease progression in a birth cohort of vertically HIV-1 infected children in Ukraine. BMC Pediatr (2010) 0.88
Cervical screening within HIV care: findings from an HIV-positive cohort in Ukraine. PLoS One (2012) 0.88
The dopamine β-hydroxylase -1021C/T polymorphism is associated with the risk of Alzheimer's disease in the Epistasis Project. BMC Med Genet (2010) 0.88
A population-based study of newly diagnosed epilepsy in infants. Epilepsia (2012) 0.88
Short- and long-term immunological and virological outcome in HIV-infected infants according to the age at antiretroviral treatment initiation. Clin Infect Dis (2011) 0.87
Mother-to-child transmission risk is increased among HIV-infected pregnant women in Ukraine with serological test results positive for syphilis. Clin Infect Dis (2008) 0.87
Dissociation between tuberculin skin test and in vitro IFN-gamma responses following neonatal BCG vaccination. J Trop Pediatr (2005) 0.86
Post-licensing safety of fosamprenavir in HIV-infected children in Europe. Pharmacoepidemiol Drug Saf (2014) 0.86
Use of neonatal antiretroviral prophylaxis for prevention of mother-to-child transmission of HIV is decreasing in Western Europe. Clin Infect Dis (2009) 0.86
Contribution of respiratory tract infections to child deaths: a data linkage study. BMC Public Health (2014) 0.86
Vertically acquired paediatric coinfection with HIV and hepatitis C virus. Lancet Infect Dis (2006) 0.85
Discovery by the Epistasis Project of an epistatic interaction between the GSTM3 gene and the HHEX/IDE/KIF11 locus in the risk of Alzheimer's disease. Neurobiol Aging (2012) 0.85
Using two on-going HIV studies to obtain clinical data from before, during and after pregnancy for HIV-positive women. BMC Med Res Methodol (2012) 0.84
Antiretroviral therapy and mother-to-child transmission of HIV-1. Expert Rev Anti Infect Ther (2004) 0.84
Missed opportunities among HIV-positive women to control viral replication during pregnancy and to have a vaginal delivery. J Acquir Immune Defic Syndr (2013) 0.84
Adherence to antiretroviral therapy during pregnancy and the first year postpartum among HIV-positive women in Ukraine. BMC Public Health (2014) 0.83